However, current standard-of-care neo/adjuvant regimens for stage II-III HER2+ breast cancer involve 2–3 chemotherapy agents plus HER2-directed therapy2, and these regimens are associated with both serious and burdensome short- and long-term toxicities3. The gene discussed is ERBB2; the disease is breast cancer.